Navigation Links
STALLERGENES: 2008: Strong Performance
Date:3/24/2009

re remarkable that it was achieved against the background of a significant investment phase relating to the rollout of the Stalair(R) program (the Stalair(R) program is the new umbrella marketing name of the range of sublingual desensitization tablets). Net R&D expenditure thus increased by 26% and represent 17.5% of sales.

Net profit increased by 17% to EUR 19.0 million and represented an 11.1% net profit margin.

The financial independence of the Group was maintained. EBITDA (gross cash surplus) grew by 14% to EUR 34.3 million, which was largely sufficient to cover investments (EUR 18.3 million), while at the same time generating, for the eighth year in a row, a positive free cash flow of EUR 4.7 million.

Stallergenes strengthened its already sound balance sheet and as a result looks forward to its expansion with confidence. The net financial debt further declined to EUR 9.6 million and only represents 0.3 times EBITDA and 12% of equity.

The Group's 2008 consolidated financial statements are available from the Group's website: http://www.stallergenes.com .

2009 outlook

As regards the Stalair(R) program, five major phase II/III clinical study results are pending. Three of these are "pivotal" studies that will lead to registrations.

The Group remains prudent to date on providing a sales guidance and expects sales growth of between 8% and 10%.

Investments will remain at a high level, without however calling into question Stallergenes' objective of maintaining an operating profitability in excess of 15% of sales and a positive free cash flow.

Significant recent transactions and events

The marketing authorization of Oralair(R) (grass pollen tablets) in its paediatric indication was delivered on 19 January 2009 by the German agency. Oralair(R) is thus mark
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
2. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
3. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
4. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
5. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
6. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
7. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
8. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
9. BIO 2008: Germany on Cutting Edge in Biomanufacturing
10. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
11. Commencement 2008: Student innovation could improve data storage, magnetic sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015   Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... supply industries, today reported financial results for the second ... half of 2015, we remain on track to achieve ... and Chief Executive Officer of the Company. "Since our ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Isolate total RNA and protein from cultured cells or tissues , ... from cultured , cells , ... Ambion's new PARIS Kit uses a fast, simple procedure based on , ... from the same experimental sample. The kit also permits separation ...
... SPEX FLUOROLOG spectrofluorometer is capable of detecting sub-picomolar ( ... ing mode FLUOROLOG spectrofluorometer with a 450-W (521 nm) xenon ... in the photon-counting mode. The bandpass was set to 4.0 ... 11020 s, with a single scan and no smoothing. Excita-490 ...
... , , , ... By James Costantin, Ph.D., Yen-Wen Chen, Ph.D., Jinfang Liao, Ph.D., , ... Molecular Devices Corporation, 3280 Whipple Road, Union City, CA 94587., ... Voltage-dependent ion channels represent a, largely untapped portion of the ...
Cached Biology Technology:A Better Way to Isolate RNA AND Protein From the Same Sample 2A Better Way to Isolate RNA AND Protein From the Same Sample 3A Better Way to Isolate RNA AND Protein From the Same Sample 4A Better Way to Isolate RNA AND Protein From the Same Sample 5Sub-Picomolar Fluorescein 2Rapid hit confirmation and early hERG liability testing using the IonWorks HT system 2Rapid hit confirmation and early hERG liability testing using the IonWorks HT system 3Rapid hit confirmation and early hERG liability testing using the IonWorks HT system 4Rapid hit confirmation and early hERG liability testing using the IonWorks HT system 5Rapid hit confirmation and early hERG liability testing using the IonWorks HT system 6Rapid hit confirmation and early hERG liability testing using the IonWorks HT system 7
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... from a remote Wisconsin lake have detected what they ... collapse of the lake,s aquatic ecosystem. The finding, ... of researchers led by Stephen Carpenter, an ecologist at ... evidence that radical change in an ecosystem can be ...
... of chemistry and T.C. Pipes endowed chair in micro ... symposium at the 241st Conference of the American Chemical ... and cost-effective nano-material that can be used to significantly ... composites. The symposium featured Lvov,s presentation on the ...
... of scientists, led by researchers at the University of ... new method for discerning the functions of previously uncharacterized ... reveal how gene products interact to bring about cellular ... 29 issue of the journal Cell. It was led ...
Cached Biology News:A tale of 2 lakes: One gives early warning signal for ecosystem collapse 2A tale of 2 lakes: One gives early warning signal for ecosystem collapse 3A tale of 2 lakes: One gives early warning signal for ecosystem collapse 4Louisiana Tech researcher presents on eco-friendly nanotechnology at national conference 2As the worm turns, its secrets are revealed 2
...
... TAMRA isomers are predominantly used for labeling ... for labeling peptides and nucleotides because they ... is often required in the conjugation processes. ... for labeling peptides and proteins. 6-TAMRA is ...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Biology Products: